Moderna: COVID-19 Vaccine Pricing to Ensure Broad Access

(Reuters) —
Vials used by pharmacists to prepare syringes used on the first day of a first-stage safety study clinical trial of the potential vaccine for COVID-19, the disease caused by the new coronavirus, at the Kaiser Permanente Washington Health Research Institute in Seattle. (AP Photo/Ted S. Warren, File)

Moderna plans to price its experimental coronavirus vaccine in a way that ensures broad access, it said on Wednesday, adding that it did not intend to conduct late-stage trials of the vaccine outside the United States.

Moderna began the U.S. government-backed trial on Monday, among a handful of companies that have started final testing of their experimental vaccines on tens of thousands of healthy volunteers.

Chief Executive Officer Stéphane Bancel declined to comment on the specific price of the vaccine on a conference call with analysts.

“We are highly aware of our obligation during the pandemic phase to be responsible in how we price the vaccine,” Bancel said.

The Financial Times reported on Tuesday, citing unnamed sources, that the company was planning to price the vaccine at $50 to $60 per course, at least $11 more than another vaccine from Pfizer Inc and BioNTech.

Moderna executives also said the enrollment for the late-stage trial was on track and the company had seen tremendous interest from clinical sites.

To Read The Full Story

Are you already a subscriber?
Click to log in!

Hamodia Logo